Truist Financial Issues Pessimistic Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM - Get Free Report) had its target price cut by investment analysts at Truist Financial from $280.00 to $260.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "hold" rating on the insurance provider's stock. Truist Financial's target price suggests a potential upside of 14.73% from the stock's previous close.

Several other brokerages have also recently weighed in on HUM. Bank of America reduced their price target on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research note on Saturday. Robert W. Baird lifted their price target on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Guggenheim assumed coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price for the company. Finally, Oppenheimer boosted their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $279.81.

Humana Stock Up 2.1%

Shares of HUM stock traded up $4.72 during trading hours on Wednesday, reaching $226.62. The company had a trading volume of 1,097,038 shares, compared to its average volume of 1,812,407. Humana has a 12 month low of $212.45 and a 12 month high of $406.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The business has a fifty day simple moving average of $236.58 and a 200-day simple moving average of $257.89. The company has a market cap of $27.35 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 1.52 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The company's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the company earned $7.23 earnings per share. On average, research analysts expect that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. denkapparat Operations GmbH bought a new position in shares of Humana during the 4th quarter valued at about $323,000. Allstate Corp bought a new position in shares of Humana during the 4th quarter valued at about $905,000. Deutsche Bank AG boosted its holdings in shares of Humana by 18.2% during the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock valued at $160,185,000 after purchasing an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Humana during the 1st quarter valued at about $1,309,000. Finally, Fred Alger Management LLC bought a new position in shares of Humana during the 4th quarter valued at about $451,000. Institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.